Business Context and Reporting Period
This Form 8-K Current Report was filed by Aethlon Medical, Inc. on August 12, 2024. The report details a significant regulatory milestone regarding the Company's Hemopurifier® technology.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a specific corporate event rather than financial performance.
Material Changes
On August 12, 2024, the Bellberry Human Research Ethics Committee granted full ethics approval to the Pindara Private Hospital. This approval enables a safety, feasibility, and dose-finding clinical trial for the Company's Hemopurifier® in patients with solid tumors who are not responding to anti-PD-1 antibodies.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the inherent uncertainties of clinical trials. The primary focus is the successful initiation of the specified clinical trial.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for specific trial protocols and timelines.
- Confirm the status of the Pindara Private Hospital's participation and patient enrollment criteria.
- Review the Company's recent 10-Q or 10-K filings for the most current financial position and cash runway.
- Monitor subsequent filings for trial initiation dates and preliminary data readouts.